Make me your Homepage
    left corner left corner
    China Daily Website

    Travel ban on director of GSK

    Updated: 2013-07-19 00:44
    By WANG HONGYI ( China Daily)

    The financial director of British pharmaceutical company GlaxoSmithKline, which is involved in suspected bribery and tax-related violations, has been banned from leaving China.

    "We have been aware of travel restrictions for Steve Nechelput since the end of June. His travel is unrestricted within China," a spokeswoman for GSK China told China Daily on Thursday.

    "It is important to stress that at no time has he been questioned or arrested, nor is he one of the individuals in detention," she said.

    Earlier this month, Chinese police accused GSK China of bribing Chinese officials and doctors so as to boost the sales of its products. So far, four senior Chinese executives at the company have been detained.

    The company has also been accused of transferring up to 3 billion yuan ($489 million) to 700 middlemen over six years to facilitate the corruption.

    As the investigation of GSK China widens, at least four multinational drug makers are also being investigated by Chinese authorities, according to a lawyer in Hong Kong whose firm offers advice on cross-border anti-corruption issues for companies.

    "We are aware of four pharmaceutical companies who are facing investigation by local anti-corruption units," Wendy Wysong, a lawyer who is the head of anti-corruption practice in the Asia-Pacific at law firm Clifford Chance, was quoted by Bloomberg as saying.

    However, she declined to identify the companies involved.

    The GSK case has sparked widening concern and disputes across China's pharmaceutical sector. The sector has been subject to various reforms of late in an attempt to control the high cost of medicines for patients in China.

    China is also a major market for international pharmaceutical companies, which are seeking growth areas to make up for slower sales in developed countries where patent protection is due to expire on certain drugs.

    According to the international healthcare market researcher IMS Health, China will overtake Japan as the world's second-biggest drugs market behind the United States by 2016.

    Shen Danyang, spokesman for the Ministry of Commerce, said the investigation by China's authorities into GSK China was part of the country's efforts to improve the business climate and create equal competition opportunities for domestic and overseas investors.

    Shen made the remarks at a news conference on Wednesday, and he said China firmly opposes any form of commercial bribery, regardless of whether the company involved is local or foreign. Any company, be it Chinese- or foreign-funded, should be subject to legal sanctions and assume legal responsibility if it breaks Chinese law, Shen said.

    As a well-known multinational company, GSK should also conduct investment activities in China in accordance with relevant Chinese laws, Shen added.

    Xinhua contributed to this story.

    8.03K
     
    ...
    Hot Topics
    A sailor from British Royal Navy destroyer HMS Daring tries to catch a mooring line to dock in the north side of the bund at Huangpu River in Shanghai December 10, 2013.
    ...
    ...
    爆操夜夜操天天操中文| 久久久久亚洲AV无码观看| 中文无码字慕在线观看| 亚洲?V无码成人精品区日韩 | 无码av不卡一区二区三区| 国产成人无码AV麻豆| 亚洲中文字幕久久精品无码喷水 | 亚洲日韩精品无码专区网址| 中文www新版资源在线| 亚洲爆乳精品无码一区二区| 国产v亚洲v天堂无码网站| 亚洲国产a∨无码中文777| 无码国内精品久久综合88| 午夜视频在线观看www中文| 亚洲无码视频在线| 精品久久久无码中文字幕天天 | 成人免费无码H在线观看不卡| 亚洲av永久无码精品古装片| A级毛片无码久久精品免费| 国产亚洲美日韩AV中文字幕无码成人| 亚洲av无码不卡私人影院| AV无码人妻中文字幕| 久久99精品久久久久久hb无码| 无码粉嫩小泬无套在线观看| 久久精品99无色码中文字幕| 中文字幕免费高清视频| 久久综合中文字幕| 波多野结衣中文字幕免费视频| 久久人妻无码中文字幕| 影院无码人妻精品一区二区| 亚洲熟妇少妇任你躁在线观看无码| 无码专区6080yy国产电影 | 日韩亚洲欧美中文在线| 国产成人一区二区三中文| 中文字幕 亚洲 有码 在线| 午夜亚洲av永久无码精品| 中文字幕无码一区二区免费| 日韩中文字幕精品免费一区| 日本中文字幕网站| 亚洲中文字幕伊人久久无码| 国内精品无码一区二区三区|